Cardinal Health Inc. reported first quarter fiscal year 2026 revenues of $64.0 billion, a 22.0% increase from $52.3 billion in the first quarter of fiscal year 2025. GAAP operating earnings rose 18.0% to $668 million, compared to $568 million in the prior-year quarter. GAAP diluted earnings per share $(EPS)$ increased 11.0% to $1.88 from $1.70. Non-GAAP operating earnings for the quarter were $857 million, up 37.0% from $625 million, while non-GAAP diluted EPS increased 36.0% to $2.55 from $1.88. Net earnings attributable to Cardinal Health, Inc. reached $450 million, an 8.0% increase from $416 million. Non-GAAP net earnings attributable to the company were $611 million, up 33.0% from $460 million. The effective tax rate for the quarter was 24.1%, while the non-GAAP effective tax rate was 21.9%. Cardinal Health raised its fiscal year 2026 non-GAAP EPS guidance to a range of $9.65 to $9.85 and increased its fiscal year 2026 non-GAAP adjusted free cash flow outlook to $3.0 to $3.5 billion. In the Pharmaceutical and Specialty Solutions segment, first quarter revenue increased 23.0% to $59.2 billion, compared to $48.0 billion in the previous year. Segment profit grew 26.0% to $667 million from $530 million, driven by brand and specialty pharmaceutical sales growth from existing and new customers. Cardinal Health anticipates completing the acquisition of Solaris Health in early November.